Skip to content
Quebec News Tribune – Lifestyle
Author:
SeaStar Medical
SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI
October 22, 2026
SeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology Award
October 14, 2026
FDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic Condition
October 7, 2026
SeaStar Medical Announces Exercise of Warrants for Approximately $3.3 Million Gross Proceeds
October 5, 2026
SeaStar Medical Announces Late-Breaking Presentation at ASN Kidney Week 2026
October 2, 2026
New ICD-10-PCS Codes are Now Available for the Use of SeaStar Medical’s SCD Therapy for Acute Kidney Injury (AKI)
October 1, 2026
SeaStar Medical Announces Chief Medical Officer, Kevin Chung, M.D., to Present at the Pediatric Paracorporeal and Extracorporeal Therapy Symposium (PPETS) 2026
September 29, 2026
SeaStar Medical Congratulates H. David Humes, M.D., on Receiving the University of Michigan 2026 Distinguished University Innovator of the Year for Development of the SCD Therapy
September 24, 2026
SeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment Conference
September 10, 2026
SeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 12, 2026
1
2
Next Page
→